Sirolimus prolongs recovery from delayed graft function after cadaveric renal transplantation

American Journal of Transplantation

Volumn 3, Issue 4, 2003, Pages 416-423

  McTaggart, Ryan A ^a   Gottlieb, Danielle ^a   Brooks, Jessica ^b   Bacchetti, Peter ^a   Roberts, John P ^a   Tomlanovich, Stephen ^a   Feng, Sandy ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

Cadaveric kidney transplantation; Complications of immunosuppression; Delayed graft function; Rapamycin; Sirolimus

Indexed keywords

RAPAMYCIN;

ADULT; AGED; ARTICLE; CADAVER DONOR; CONVALESCENCE; DELAYED GRAFT FUNCTION; DIALYSIS; DISEASE ASSOCIATION; DRUG CHOICE; FEMALE; GRAFT FAILURE; GRAFT REJECTION; HAZARD ASSESSMENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFORMATION PROCESSING; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NONBIOLOGICAL MODEL; ORGAN DONOR; POSTOPERATIVE PERIOD; RECIPIENT; SCORING SYSTEM; SENSITIZATION; TIME;

ADULT; CADAVER; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; SIROLIMUS;

EID: 0038666511     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-6143.2003.00078.x     Document Type: Article

References (42)

1. Opelz G, Sasaki N, Terasaki PI. Prediction of long-term kidney transplant survival rates by monitoring early graft function and clinical grades. Transplantation 1978; 25: 212-215.
2. Sanfilippo F, Vaughn WK, Spees EK, Lucas BA. The detrimental effects of delayed graft function in cadaver donor renal transplantation. Transplantation 1984; 38: 643-648.
3. Shoskes DA, Halloran PF. Delayed graft function in renal transplantation: etiology, management and long-term significance. J Urol 1996; 155: 1831-1840.
4. Shoskes DA, Cecka JM. Deleterious effects of delayed graft function in cadaveric renal transplant recipients independent of acute rejection. Transplantation 1998; 66: 1697-1701.
5. McLaren AJ, Jassem W, Gray DW, Fuggle SV, Welsh KI, Morris PJ. Delayed graft function: risk factors and the relative effects of early function and acute rejection on long-term survival in cadaveric renal transplantation. Clin Transplant 1999; 13: 266-272.
6. Kyllonen LE, Salmela KT, Eklund BH et al. Long-term results of 1047 cadaveric kidney transplantations with special emphasis on initial graft function and rejection. Transpl Int 2000; 13: 122-128.
7. Halloran PF, Hunsicker LG. Delayed graft function: state of the art, November 10-11, 2000. Summit meeting, Scottsdale, Arizona, USA. Am J Transplant 2001; 1: 115-120.
8. Troppmann C, Gillingham KJ, Benedetti E et al. Delayed graft function, acute rejection, and outcome after cadaver renal transplantation. The multivariate analysis. Transplantation 1995; 59: 962-968.
9. Ojo AO, Wolfe RA, Held PJ, Port FK, Schmouder RL. Delayed graft function: risk factors and implications for renal allograft survival. Transplantation 1997; 63: 968-974.
10. Troppmann C, Gillingham KJ, Gruessner RW et al. Delayed graft function in the absence of rejection has no long-term impact. A study of cadaver kidney recipients with good graft function at 1 year after transplantation. Transplantation 1996; 61: 1331-1337.
11. Novick AC, Hwei HH, Steinmuller D et al. Detrimental effect of cyclosporine on initial function of cadaver renal allografts following extended preservation. Results of a randomized prospective study. Transplantation 1986; 42: 154-158.
12. Canafax DM, Torres A, Fryd DS et al. The effects of delayed function on recipients of cadaver renal allografts. A study of 158 patients randomized to cyclosporine or ALG-azathioprine. Transplantation 1986; 41: 177-181.
13. Dumler F. Effect of cyclosporine on the rate of renal function recovery after renal transplantation. Henry Ford Hospital Med J 1989; 37: 24-27.
14. Vincenti F, Grinyo J, Ramos E et al. Can antibody prophylaxis allow sparing of other immunosuppressives? Transplant Proc 1999; 31: 1246-1248.
15. Chang GJ, Mahanty HD, Vincenti F et al. A calcineurin inhibitorsparing regimen with sirolimus, mycophenolate mofetil, and anti-CD25 mAb provides effective immunosuppression in kidney transplant recipients with delayed or impaired graft function. Clin Transplant 2000; 14: 550-554.
16. Chang GJ, Adey D, Tomlanovich S, Amend W, Vincenti F. Early histology, acute rejection, and outcome in renal transplant patients with severe delayed graft function treated with a calcineurin inhibitor-free regimen [abstract]. J Am Soc Nephrol 2001; 12: 882A.
17. Port FK, Bragg-Gresham JL, Metzger RA et al. Donor characteristics associated with reduced graft survival: an approach to expanding the pool of kidney donors. Transplantation 2002; 74: 1281-1286.
18. Irish WD, McCollum DA, Tesi RJ, Owen AB, Schnitzler M. A nomogram for predicting the likelihood of delayed graft function in adult cadaveric (CAD) renal transplant recipients [abstract]. Am J Transplant 2001; (Suppl.1): 254.
19. Ojo A, Sablinski T, Roberts JP et al. Prospectively validated scoring index to predict delayed graft function (DGF) in cadaveric renal transplantation [abstract]. Am J Transplant 2002; 2 (Suppl. 3): 275.
20. Nyberg SL, Matas AJ, Rogers M et al. Donor scoring system for cadaveric renal transplantation. Am J Transplant 2001; 1: 162-170.
21. DiJoseph JF, Sharma RN, Chang JY. The effect of rapamycin on kidney function in the Sprague-Dawley rat. Transplantation 1992; 53: 507-513.
22. Kahan BD. Sirolimus: a comprehensive review. Expert Opin Pharmacother 2001; 2: 1903-1917.
23. Olyaei AJ, de Mattos AM, Bennett WM. Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies. Curr Opin Crit Care 2001; 7: 384-389.
24. Morales JM, Wramner L, Kreis H et al. Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients. Am J Transplant 2002; 2: 436-442.
25. Sehgal SN. Rapamune (Sirolimus, rapamycin): an overview and mechanism of action. Ther Drug Monit 1995; 17: 660-665.
26. Gallo R, Padurean A, Jayaraman T et al. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation 1999; 99: 2164-2170.
27. Burke SE, Lubbers NL, Chen YW et al. Neointimal formation after balloon-induced vascular injury in Yucatan minipigs is reduced by oral rapamycin. J Cardiovasc Pharmacol 1999; 33: 829-835.
28. Lieberthal W, Fuhro R, Andry CC et al. Rapamycin impairs recovery from acute renal failure: role of cell-cycle arrest and apoptosis of tubular cells. Am J Physiol Renal Physiol 2001; 281: F693-F706.
29. Koning OH, Ploeg RJ, van Bockel JH et al. Risk factors for delayed graft function in cadaveric kidney transplantation, a prospective study of renal function and graft survival after preservation with University of Wisconsin solution in multi-organ donors. European Multicenter Study Group. Transplantation 1997; 63: 1620-1628.
30. Katznelson S, Bhaduri S, Cecka JM. Clinical aspects of sensitization. Clin Transpl 1997; 13: 285-296.
31. Feucht HE, Lederer SR, Kluth B. Humoral alloreactivity in recipients of renal allografts as a risk factor for the development of delayed graft function. Transplantation 1998; 65: 757-758.
32. Matas AJ, Gillingham K, Payne WD et al. Should I accept this kidney? Clin Transplant 2000; 14: 90-95.
33. Perez Fontan M, Rodriquez-Carmona A, Bouza P et al. Outcome of grafts with long-lasting delayed function after renal transplantation. Transplantation 1996; 62: 42-47.
34. Giral-Classe M, Hourmant M, Cantarovich D et al. Delayed graft function of more than six days strongly decreases long-term survival of transplanted kidneys. Kidney Int 1998; 54: 972-978.
35. Feucht HE, Opelz G. The humoral immune response towards HLA class II determinants in renal transplantation. Kidney Int 1996; 50: 1464-1475.
36. McKenna RM, Takemoto SK, Terasaki PI. Anti HLA antibodies after solid organ transplantation. Transplantation 2000; 69: 319-326.
37. Mauiyyedi S, Pelle PD, Saidman S et al. Chronic humoral rejection: identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries. J Am Soc Nephrol 2001; 12: 574-582.
38. Crespo M, Pascual M, Tolkoff-Rubin N et al. Acute humoral rejection in renal allograft recipients: I. Incidence, serology and clinical characteristics. Transplantation 2001; 71: 652-658.
39. Yokoyama I, Uchida K, Kobayashi T, Tominaga Y, Orihara A, Takagi H. Effect of prolonged delayed graft function on long-term graft outcome in cadaveric kidney transplantation. Clin Transplant 1994; 8: 101-106.
40. Fernandez-Juarez G, Marcen R, Pascual J et al. Prolonged delayed graft function decreases graft survival in transplant patients taking cyclosporine. Transplant Proc 2002; 34: 338-339.
41. Lehtonen SR, Isoniemi HM, Salmela KT et al. Long-term graft outcome is not necessarily affected by delayed onset of graft function and early acute rejection. Transplantation 1997; 64: 103-107.
42. Cacciarelli T, Sumrani N, Delaney V, Hong JH, DiBenedetto A, Sommer BG. The influence of delayed renal allograft function on long-term outcome in the cyclosporine era. Clin Nephrol 1993; 39: 335-339.